ArticleActa pharmacologica Sinica2016

OL3, a novel low-absorbed TGR5 agonist with reduced side effects, lowered blood glucose via dual actions on TGR5 activation and DPP-4 inhibition.

Shan-Yao Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.